memantine
AssetSmall moleculeAlso CKD-355A, D797, Memantine - Extended Release (ER), Memantine HCl
Uncompetitive NMDA receptor antagonist protecting against glutamate excitotoxicity
- Stage
- Approved
- Modality
- Small molecule
- Target
- GRIN2B
- Indications
- 22
- Trials
- 140
- Developers
- 6
Indications
22Alzheimer's disease
Approvedema.europa.eu7 Oct 2026
Dementia
Approvedaccessdata.fda.gov7 Oct 2026
Moderate to Severe Alzheimer's Disease
Approvedema.europa.eu7 Oct 2026
19 more
- Targets and what it contains3
- Owner and partners6
- Trials140
- Evidence for its targets2
- Competitors12
- Signals7
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026 · 33 sources